ClinicalTrials.gg
CompletedNCT07049562Updated Jul 3, 2025

Study on the Mass Balance of [14C]HRS-8427 for Injection in Healthy Chinese Subjects

A Phase 1 interventional study of HRS-8427 in Healthy Cninese Adult Male, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-03.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

To evaluate the absorption, metabolism and excretion after a single intravenous infusion of [14C]HRS-8427 in healthy Chinese subjects

02

Conditions studied

  • Healthy Cninese Adult Male
03

In context

Lead sponsor

Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male ages 18\~45 years, inclusive;
  2. The body weight should be no less than 50 kg, and the (BMI) should be within the range of 19.0 kg/m2 to 26.0 kg/m2, inclusive;
  3. Subjects without sperm donation or fertility plan, and agree to adopt highly medically effective measurements during the trial and within 3 months after the last dose;
  4. Participants voluntarily sign the form before the trial, can communicate well with the researcher, have a full understanding of the trial content, process and possible adverse reactions, and can complete the trial in accordance with the protocol.

Exclusion criteria

Exclusion Criteria:

  1. A history of allergies to food, drugs allergic constitution;
  2. History or presence of seriousmediacl diseases judged by the investigator as not suitable for the study;
  3. Perianal diseases with regular or ongoing bloody stools, irritable bowel syndrome, and inflammatory bowel disease;
  4. Habitual constipation or diarrhea;
  5. Those who have undergone major surgical operations within the three months prior to screening; Or those who have undergone surgery that may affect the in vivo process or safety evaluation of the studied drug; Or those who plan to undergo surgical operations during the research period;
  6. With abnormal and comprehensive physical examinations, vital signs, or laboratory examinations
  7. Abnormal 12-lead and determined by the researcher as unsuitable to participate in this study
  8. Tested positive for antibodies, surface antigen, , or Treponema pallidum antibodies;
  9. Those who have used other clinical trial drugs within 3 months before the trial or plan to participate in other clinical trials during this study period;
  10. Those have experienced blood loss or donated up to 300 mL of blood, or have received blood transfusion or used blood products, or plan to donate blood during the trial or within 1 month after the end of the trial;
  11. Abuse of alcohol or drugs
  12. Heavy smokers or caffeine addicts.
  13. Those engaged in long-term exposure to radioactive conditions; Or those who have had significant radioactive exposure within one year before the test or have participated in radiopharmaceutical tests within one year;
  14. Those who cannot accept a uniform diet or have special dietary requirements;
  15. Participants who may be unable to complete this study for other reasons or who the researcher deems should not be included.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Treatment group A: [14C] HRS-8427

    Drug: HRS-8427

Interventions

  • \[14C\] HRS-8427 for injection

06

What researchers measure

Primary outcomes

  1. The total radioactive recovery rate and cumulative total radioactive recovery rate at each time interval in excreta (urine and feces)

    Time frame: 0~120hours

  2. The percentage (%AUC) of the potent drug and its metabolites in plasma, urine and feces to the administered dose

    Time frame: 0~120hours

  3. Tmax

    Time frame: 0~48hours

  4. Cmax

    Time frame: 0~48hours

  5. t1/2

    Time frame: 0~48hours

  6. MRT

    Time frame: 0~48hours

  7. AUC

    Time frame: 0~48hours

Secondary outcomes

  1. Tmax

    Time frame: 0~48hours

  2. Cmax

    Time frame: 0~48hours

  3. MRT

    Time frame: 0~48hours

  4. AUC

    Time frame: 0~48hours

  5. t1/2

    Time frame: 0~48hours

  6. Adverse events

    Time frame: 0~120hours

07

Study locations

1 site
  • First Affiliated Hospital of Shandong First Medical University (Shandong Provincial Qianfoshan Hospital)
    Jinan, Shandong 250014, China
08

References and documents

Publications

  • Yin T, Qu B, Zhang Q, Xu S, Wu Y, Jiang H, Huang Y, Hu W. Pharmacokinetics, safety, and tolerability of HRS-8427, a novel anti-carbapenem-resistant cephalosporin, in healthy subjects. Antimicrob Agents Chemother. 2026 Apr;70(4):e0069425. doi: 10.1128/aac.00694-25. Epub 2026 Mar 3. PubMed 41773934 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2025 to primary completion in Jun 2025, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2025
First posted
Jul 3, 2025
StartActual
May 21, 2025
Primary completionActual
Jun 18, 2025
CompletionActual
Jun 18, 2025
Last update
Jul 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07049562
Responsible party
Sponsor
First posted
Jul 3, 2025
Start date
May 21, 2025
Primary completion
Jun 18, 2025
Completion
Jun 18, 2025
Last update
Jul 3, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HRS-8427

Start the discussion